Results of Operations and Financial Condition. On August 11, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Sec…

of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD. Forward-Looking Statements This communication relates to a proposed business combination transaction between MiMedx Group, Inc. (“MiMedx”) and Sanara MedTech Inc. (“Sanara”). This communication contains certain forward-looking statements within the meaning of the Private Securities Litigation Re…

Entry into a Material Definitive Agreement. Agreement and Plan of Merger On July 29, 2026, Sanara MedTech Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, MiMedx Group, Inc., a Florida corporation (“Parent”) and Mustang Merger Sub, Inc., a Texas corporation and a wholly-owned subsidiary of Parent (“Merger Subsidiary”). Upon the terms and conditions set forth in the Merger Agreement, Merger Subsidiary will be merged with and i…

Termination of a Material Definitive Agreement. As previously disclosed, on March 20, 2023, Sanara MedTech Inc. (the “Company”) entered into a Transaction Advisory Services Agreement (the “Services Agreement”) with The Catalyst Group, Inc., a Texas corporation (“Catalyst”), effective as of March 1, 2023. Pursuant to the Services Agreement, Catalyst agreed to perform certain transaction advisory, business and organizational strategy, finance, marketing, operational and strategic planning, rela…

Results of Operations and Financial Condition. On May 11, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Secur…

Results of Operations and Financial Condition. On March 24, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 1…

Results of Operations and Financial Condition. On January 23, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the fourth quarter and full year 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes o…

Results of Operations and Financial Condition. On November 11, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing that it has initiated a strategic realignment of its business, discontinuing operations of its Tissue Health Plus. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall n…

Results of Operations and Financial Condition. On November 12, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of…

CEO — Seth D. Yon: Seth D. Yon was promoted to President and Chief Executive Officer, with Ronald T. Nixon stepping down as CEO but remaining as Executive Chairman.

Results of Operations and Financial Condition. On August 13, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Sec…

Chief Accounting Officer and Chief Administrative Officer — Michael D. McNeil: Michael D. McNeil is retiring from his positions with a successor named and potential consulting arrangement.

Results of Operations and Financial Condition. On May 14, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Secur…

Entry into a Material Definitive Agreement. CarePICS Acquisition On April 1, 2025 (the “Closing Date”), Sanara MedTech Inc., a Texas corporation (the “Company”), entered into a Unit Purchase Agreement (the “Purchase Agreement”), by and among the Company, Tissue Health Plus, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (the “Purchaser”), CarePICS, LLC, a Delaware limited liability company (“CarePICS”), the holders of CarePICS’s outstanding units (each, a…

Other Events. On March 31, 2025, the Company, pursuant to its option under its previously disclosed Term Loan Agreement with CRG Servicing LLC, dated as of April 17, 2024 (as amended on March 19, 2025, the “Loan Agreement”) borrowed an additional $12.25 million under the Loan Agreement (the “Third Borrowing”). As previously disclosed, the Loan Agreement provides for up to a $55.0 million term loan facility, $15.0 million of which was borrowed on April 17, 2024 (the “First Borrowing”) and $15.…

Completion of Acquisition or Disposition of Assets. The information set forth in

Results of Operations and Financial Condition. On March 25, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 1…

Entry into a Material Definitive Agreement. The information set forth in

Chief Financial Officer — Elizabeth B. Taylor: Appointment of a new Chief Financial Officer with significant experience in senior financial roles.

Other Events. Licensing and Distribution Agreement On January 16, 2025 (the “Execution Date”), the Company entered into a Licensing and Distribution Agreement (the “License Agreement”), by and between the Company and Biomimetic Innovation Limited, a privately-held medical device company headquartered in Shannon, Co. Clare Ireland (“BMI”), pursuant to which the Company acquired the exclusive U.S. marketing, sales and distribution rights to OsStic ® Synthetic Injectable Structural Bio-Adhesive…

Results of Operations and Financial Condition. On January 21, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the fourth quarter and full year 2024. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes o…

Results of Operations and Financial Condition. On November 12, 2024, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. In addition, the Company is furnishing a copy of an earnings presentation (the “Presentation”) that the Company intends to use, in whole or in part, in…

Director — James W. Stuckert: Mr. Stuckert resigned from the Board and was succeeded by Keith Myers.

Chief Executive Officer — Ronald T. Nixon: Ronald T. Nixon was promoted to Chief Executive Officer and entered into an employment agreement with the company.

Other Events. On September 10, 2024, Sanara CMP LLC, a wholly owned subsidiary of the Company (“Sanara CMP”), entered into a Unit Purchase Agreement (the “Unit Purchase Agreement”) with ChemoMouthpiece, LLC (“CMp”), pursuant to which Sanara CMP purchased 100,674.72 common units in CMp for $5.0 million, which represents approximately 6.64% of the issued and outstanding membership interests of CMp immediately following such purchase. CMp is a privately held medical device company that develops…